Sign inJoin waitlistJoin the waitlist

Brian Modena

Physician · Modena Allergy and Asthma II Inc.

Credentials: · · · ·

History

Modena Allergy and Asthma II Inc.
2026–Present

University of Pittsburgh
2013–2014
Scripps Clinic and Green Hospital
2006–2009
The Scripps Research Institute, MS, 2015
West Virginia University School of Medicine
2002–2006

Research

Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways
American Journal of Respiratory and Critical Care Medicine · 2014 · First of 13 authors · 163 citations
Gene Expression Correlated with Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease
American Journal of Respiratory and Critical Care Medicine · 2017 · First of 12 authors · 124 citations
Gene Expression in Biopsies of Acute Rejection and Interstitial Fibrosis/Tubular Atrophy Reveals Highly Shared Mechanisms That Correlate With Worse Long-Term Outcomes
American Journal of Transplantation · 2016 · First of 18 authors · 93 citations

Sally Wenzel
9 papers
Andrew White
8 papers
Eugene Bleecker
5 papers
Naftali Kaminski
5 papers
Nizar Jarjour
5 papers
Benjamin Gaston
4 papers
Ronald Simon
4 papers
Serpil Erzurum
4 papers
William Busse
4 papers
John Tedrow
3 papers
KW
Katharine Woessner
3 papers
Kevin Cook
3 papers · 2 as a fellow

Grants

Genomic Analysis of Epithelial Growth and Repair Mechanisms in Aspirin Exacerbated Respiratory Disease
National Heart, Lung, and Blood Institute · K23
Contact PI · $502.5K · National Jewish Health
2018–2021

Clinical trials

A Pilot Study to Assess the Suitability of the HealthBeacon Injection Care Management System (ICMS) as a Remote Therapeutic Monitoring (RTM) Device
Principal investigator · Unknown
HealthBeacon Plc
2022–2023
Withings Pulse Wave Velocity and Blood Pressure Study
Principal investigator · Completed
Scripps Translational Science Institute
2017
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2022–2027
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Site PI · Available
Cogent Biosciences, Inc.